Trident Lifeline Ltd Quarterly Results
Q1 FY26-27 Results Summary
Revenue
The revenue stands at ₹33.72 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 32.49 per cent from ₹49.95 crore. This corresponds to a year-on-year *(YoY) growth of 42.82 per cent.
Operating Profit
Operating Profit stands at ₹8.52 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 22.40 per cent from ₹10.98 crore. This corresponds to a year-on-year *(YoY) growth of 64.80 per cent.
PBDT
PBDT stands at ₹8.23 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 30.55 per cent from ₹11.85 crore. This corresponds to a year-on-year *(YoY) growth of 52.69 per cent.
Profit Before Tax
Profit Before Tax stands at ₹6.61 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 37.76 per cent from ₹10.62 crore. This corresponds to a year-on-year *(YoY) growth of 68.19 per cent.
Net Profit
Net Profit stands at ₹5.07 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 25.44 per cent from ₹6.80 crore. This represents a 82.37 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Market News
Trident Lifeline Ltd Earnings
- YOY
- QOQ
Trident Lifeline Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Trident Lifeline Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Trident Lifeline Ltd Financial Reports
Trident Lifeline Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Trident Lifeline | -0.63% | 4.95% | 11.19% | 15.08% | 14.18% | 1.92% |
| Jenburkt Pharma | -0.02% | 1.43% | -0.73% | -10.46% | 3.54% | -3.40% |
| Haleos Labs Limited | 3.26% | 0.75% | 2.04% | 11.56% | 16.06% | 29.82% |
| Medicamen Biotec | -0.44% | 9.76% | 21.05% | 23.59% | -1.31% | -17.97% |
| Astal Lab | -1.60% | -3.07% | -5.41% | 2.84% | -1.24% | -5.46% |
| Ambalal Sarabhai | 0.95% | -3.37% | -12.29% | 28.21% | 75.35% | 32.96% |
| Aarey Drugs | 2.41% | 3.83% | 18.94% | 21.57% | 41.34% | 37.03% |
Company Info
Company Information
Chairman/ED & CEO : Hardik J Desai
ED / MD / Promoter : Shravan Harikrishna Patel
Non-Exec & Non-Independent Dir : Maniya H Desai
Independent Non Exe. Director : Mishal Shailesh Patel
Independent Non Exe. Director : Falguni Bhavesh Jariwala
Whole-time Director : Rupaben Chetanbhai Jariwala
Director & CFO : ASHISH ANANDSINGH BAFNA
Company Sec. & Compli. Officer : Nikita Sharma